Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Market-Beating Community Intelligence
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Unrealistic decline after last earnings, only because they weren't as huge as expected based on previous results. Great growth opportuity, and customised therapies are definitely the future of healthcare. MYGN is a good lower priced company for this, in the same vein as the sucessful CELG